Monitor the proxy vote and Nasdaq compliance plan for the merger closing. The CVR milestone for SENTI-202 is a binary catalyst but distant. The equity commitment at the Minimum Price suggests severe dilution for existing common shareholders. Watch for any delays in the merger or Nasdaq delisting risk.
Price Chart
Executive Summary
Senti Biosciences filed a DEFA14A (8-K) reporting $2.0M in additional senior secured convertible notes issued to NSG BioInnovation Fund and a $2.5M equity commitment from a Celadon affiliate at the Nasdaq Minimum Price, contingent on closing a merger with a Celadon entity. The merger includes a contingent value right (CVR) of up to $60M tied to SENTI-202 milestones. The company is raising bridge financing to support the merger and Nasdaq compliance, but the terms are highly dilutive and the company remains in a distressed position with an $11M market cap.
Key Facts
- Issued $2.0M in Senior Secured Convertible Notes to NSG BioInnovation Fund on September 3, 2026.
- Entered equity commitment letter with Celadon affiliate for $2.5M of common stock at Nasdaq Minimum Price, contingent on merger closing.
- Merger Agreement dated July 14, 2026 with a Celadon affiliate; CVR of up to $60M for SENTI-202 regulatory and sales milestones.
- Notes mature November 23, 2026, convertible at $0.6261 per share, with 200% redemption on maturity or default.
- Company must retain at least $600K cash post-closing and submit a Nasdaq compliance plan.
- Preliminary proxy filed July 21, 2026 for shareholder approval of the transactions.
Financial Impact
$2.0M additional convertible debt and $2.5M equity commitment at distressed pricing; CVR provides up to $60M contingent upside
Risk Factors
- Nasdaq delisting if compliance plan is not accepted
- Severe dilution from convertible notes and equity commitment at Minimum Price
- Merger may not close by December 31, 2026 outside date
- CVR milestones are contingent and may never pay out
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-060602 |
| Exhibit: ex102_equitycommitmentlett.htm | 0001628280-26-060602 |
| Document: snti2026defa-14aeclandnsg2.htm | 0001628280-26-060602 |
| Document: 0001628280-26-060602-index-headers.html | 0001628280-26-060602 |
| Document: 0001628280-26-060602-index.html | 0001628280-26-060602 |
| Document: 0001628280-26-060602.txt | 0001628280-26-060602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.1720 | awaiting T+5 | — | $0.1750 (−1.74%) |
Oct 13, 2026 13d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1750 (−27.33%) |
Oct 13, 2026 13d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1750 (+27.33%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1750 (+44.55%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1750 (+42.81%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1750 (−47.38%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1750 (+47.38%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1750 (+54.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers